Rab Prinjha, Head At GSK To Speak At 2nd Epigenetics Conference Nov 8-9, 2012 Boston
Rab Prinjha, Interim Head of Epinova Epigenetics DPU and Head of Biology at GlaxoSmithKline will give a featured presentation on "Epigenetic Modification in the Treatment of Immunoinflammatory Diseases" at the 2nd Epigenetics in Drug Discovery Conference taking place on Nov 8-9, 2012 in Boston, MA.
- San Diego, CA (1888PressRelease) October 11, 2012 - Dr. Prinjha joined GlaxoSmithKline as Director of External Drug Discovery in 1997, focusing on their business development opportunities, review approval and management of drug discovery alliances. In 2010, he became Head of Target Progression at GSK and worked on the identification of novel epigenetic targets for immuno-inflammation drug discovery and generation of biological rationale for target progression through the portfolio (target identification to FTIH). In January 2012, Dr. Prinjha because Interim Head of Epinova Epigenetics DPU and Head of Biology at GSK.
GTC's 2nd Epigenetics in Drug Discovery conference is the only epigenetics conference that brings together a balanced mix of leading experts from the industry and academia to collaborate on the latest cutting edge research on novel mechanisms, therapeutics, technologies and diagnostics for epigenetics drug discovery. Some key discussions around epigenetics drug discovery at the conference include: 1) The role of epigenetics in human diseases such as cancer, leukaemia, neurodegenerative conditions, neuropsychiatric disorders, inflammation, etc. 2) Cutting edge research from GlaxoSmithKline, Epizyme, Genentech, Constellation, Cellzome, RaNA Therapeutics, Pfizer, Harvard, Massachusetts Institute of Technology, etc.
For more information, please visit www.gtcbio.com
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam